ADC Therapeutics secondary offering
We advised ADC Therapeutics on the registered secondary offering of its shares
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Roivant Sciences $230 million stock offering
We advised the company on its SEC-registered offering
Integer Holdings $500 million convertible senior notes offering
The 2.125% convertible notes are due 2028
Pacific Biosciences $201.25 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Precigen $75 million follow-on offering
We advised Precigen on the SEC-registered offering
Deciphera Pharmaceuticals $135.1 million common stock offering
The common stock is listed on the Nasdaq Global Select Market
New Horizon Health HK$781.7 million top-up placement of shares
We advised New Horizon Health on the top-up placement
Jinxin Fertility Group HK$1.17 billion top-up placement of shares
The shares are listed on the Hong Kong Stock Exchange
Novavax $175.25 million convertible senior notes offering
The 5% convertible notes are due 2027
Terns Pharmaceuticals $86 million stock offering
The stock is listed on the Nasdaq Global Select Market